Avandia Safety Rhetoric Ramps Up Ahead Of Advisory Committee Review
Executive Summary
Participants in the ongoing safety debate over GlaxoSmithKline's Avandia (rosiglitazone) are refining their arguments ahead of the July 13-14 joint FDA advisory committee meeting on the troubled thiazolidinedione's future